Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| EUDRACTnr: 2006-001279-39 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to further assess the safety of dasatinib in imatinib intolerant or resistant patients with chronic phase chronic myeloid leukemia, advanced phase chronic myeloid leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia. The efficacy of the drug in this kind of patients will also further be documented.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dasatinib | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence and severity of drug-related adverse events. |
| Measure | Description | Time Frame |
|---|---|---|
| Chronic Phase CML: Cytogenetic and Hematologic Response | ||
| Advanced Phase CML and Philadelphia positive ALL: Hematologic Response | ||
| Time to and duration of Cytogenetic and Hematologic Response |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Local Institution | Budapest | Hungary | ||||
| Local Institution |
Not provided
Not provided
Not provided
Not provided
Not provided
| Bologna |
| Italy |
| Local Institution | Orbassano (To) | Italy |
| Local Institution | Roma | Italy |
| Local Institution | Nijmegen | Netherlands |
| Local Institution | Rotterdam | Netherlands |
| Local Institution | Gdansk | Poland |
| Local Institution | Katowice | Poland |
| Local Institution | Krakow | Poland |
| Local Instiution | Lodz | Poland |
| Local Institution | Lublin | Poland |
| Local Institution | Warsaw | Poland |
| Local Institution | Moscow | Russia |
| Local Institution | Saint Petersburg | Russia |
| Local Institution | Cambridge | Cambridgeshire | United Kingdom |
| Local Institution | Glasgow | Central | United Kingdom |
| Local Institution | London | Greater London | United Kingdom |
| Local Institution | Liverpool | Merseyside | United Kingdom |
| Local Institution | Newcastle | Tyne and Wear | United Kingdom |
| Local Institution | Birmingham | West Midlands | United Kingdom |
| ID | Term |
|---|---|
| D015464 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| D054198 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| D000092122 | Bronchiolitis Obliterans Syndrome |
| ID | Term |
|---|---|
| D007951 | Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009196 | Myeloproliferative Disorders |
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007945 | Leukemia, Lymphoid |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D000092124 | Organizing Pneumonia |
| D001989 | Bronchiolitis Obliterans |
| D001988 | Bronchiolitis |
| D001991 | Bronchitis |
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D006086 | Graft vs Host Disease |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069439 | Dasatinib |
| ID | Term |
|---|---|
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011743 | Pyrimidines |
Not provided
Not provided